Oncology Diagnostics Program
Cancer
DiscoveryActive
Key Facts
About Aptus Biosciences
Aptus Biosciences is a private, pre-revenue diagnostics company focused on reinventing aptamer technology for clinical applications. The company is developing a platform of chemically modified DNA aptamers designed as high-specificity, high-affinity reagents for detecting disease biomarkers. Its initial pipeline targets major therapeutic areas including neurology, oncology, cardiology, and infectious diseases, with the goal of enabling earlier and more accurate diagnosis. As an early-stage venture, Aptus is likely seeking partnerships and investment to advance its programs from platform development into validated diagnostic assays.
View full company profileTherapeutic Areas
Other Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Not Specified (Oncology Focus) | Narwhal Bio | Pre-clinical |
| EDM Platform for Genetic Medicine | Coastar Therapeutics | Pre-clinical |
| CO-1 | Caedo Oncology | Pre-clinical |
| Anti-CD99 monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Anti-HLA class I monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Triapine® | Nanopharmaceutics | Clinical |
| Ammonium Tetrathiomolybdate | Nanopharmaceutics | Clinical |
| Aza-TdC | Nanopharmaceutics | Clinical |
| Undisclosed Oncology Program(s) | Cell BioEngines | Phase 1 |
| No-alpha IL-2 Mutein | SarcoMed USA | Pre-clinical |
| PMIS Therapeutic | NaturemiRI | Preclinical/Clinical (unspecified) |
| AUM302 (formerly IBL-302) | Inflection Biosciences | Pre-clinical (partnered) |